(5-((4-methoxybenzyl)oxy)-6-methylpyridine-3,4-diyl)dimethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-((4-methoxybenzyl)oxy)-6-methylpyridine-3,4-diyl)dimethanol
• 英文别名: [4-(Hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]-6-methylpyridin-3-yl]methanol；[4-(hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]-6-methylpyridin-3-yl]methanol
• 化学式: C₁₆H₁₉NO₄
• 分子量: 289.331
• InChiKey: AULZUHGMJADIEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  71.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (5-((4-methoxybenzyl)oxy)-6-methylpyridine-3,4-diyl)dimethanol 在 三乙基硅烷 、 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 35.17h， 生成 (5-hydroxy-6-methylpyridine-3,4-diyl)bis(methylene) bis(2-(prop-2-yn-1-yloxy)propanoate)
  参考文献：
  名称：

  [EN] POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT
  [FR] CONJUGUÉ DE POLYMÈRE COMPRENANT UN AGENT BIOACTIF

  摘要：

  本发明一般涉及聚合物-生物活性剂共轭物，用于向受试者递送生物活性剂。该聚合物-生物活性剂共轭物在聚合物骨架中含有三唑基团和从喹诺酮、非甾体类抗炎药和二者混合物中选择的生物活性基团。本发明还涉及使用点击环加成化学反应制备聚合物共轭物的方法，适用于制备聚合物共轭物的单体-生物活性剂共轭物，以及包含聚合物共轭物的药品产品，用于术后护理以治疗或预防感染、提供镇痛和治疗炎症。

  公开号：

  WO2017041142A1
• 作为产物：
  描述：

  吡哆醇盐酸盐 、 4-甲氧基氯苄 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 42.75h， 以26%的产率得到(5-((4-methoxybenzyl)oxy)-6-methylpyridine-3,4-diyl)dimethanol
  参考文献：
  名称：

  [EN] POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT
  [FR] CONJUGUÉ POLYMÈRE POUR LA DÉLIVRANCE D'UN AGENT BIOACTIF

  摘要：

  本发明一般涉及用于向受试者传递生物活性剂的聚合物-生物活性剂共轭物。聚合物-生物活性剂共轭物在聚合物骨架中含有三唑基团和从前列腺素类似物、β-受体阻滞剂和二者的混合物中选择的生物活性基团。本发明还涉及使用点击化学反应制备聚合物共轭物的方法，适用于制备聚合物共轭物的单体-生物活性剂共轭物，以及包含用于治疗青光眼的聚合物共轭物的药物产品。

  公开号：

  WO2014134689A1

文献信息

• POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT
  申请人：POLYACTIVA PTY LTD

  公开号：US20160000929A1

  公开（公告）日：2016-01-07

  The presentinvention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from prostaglandin analogues, β-blockers and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.

  本发明通常涉及聚合物-生物活性剂共轭物，用于将生物活性剂传递给对象。聚合物-生物活性剂共轭物在聚合物骨架中含有三唑基团和从前列腺素类似物、β受体阻滞剂和其混合物中选择的生物活性基团。本发明还涉及使用点击化学反应制备聚合物共轭物的方法，适用于制备聚合物共轭物的单体-生物活性剂共轭物，以及包含聚合物共轭物的制药产品，用于治疗青光眼。
• Polymer conjugate for delivery of a bioactive agent
  申请人：POLYACTIVA PTY LTD

  公开号：US10113033B2

  公开（公告）日：2018-10-30

  The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety comprising prostaglandin analogues. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.

  本发明总体上涉及用于向受试者输送生物活性剂的聚合物-生物活性剂共轭物。聚合物-生物活性剂共轭物的聚合物骨架中含有三唑分子，生物活性分子包括前列腺素类似物。本发明还涉及利用点击化学反应制备聚合物共轭物的方法、适用于制备聚合物共轭物的单体-生物活性剂共轭物，以及包含用于治疗青光眼的聚合物共轭物的药物产品。
• Polymer conjugate comprising a bioactive agent
  申请人：POLYACTIVA PTY LTD

  公开号：US10758626B2

  公开（公告）日：2020-09-01

  The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from quinolones, NSAIDs and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click cycloaddition chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the post-surgical care to treat or prevent infections, provide analgesia and treat inflammation.

  本发明总体上涉及用于向受试者输送生物活性剂的聚合物-生物活性剂共轭物。聚合物-生物活性剂共轭物的聚合物骨架中含有三唑分子和选自喹诺酮类、非甾体抗炎药及其混合物的生物活性分子。本发明还涉及使用单击环化化学反应制备聚合物共轭物的方法、适用于制备聚合物共轭物的单体-生物活性剂共轭物，以及包含聚合物共轭物的用于手术后治疗或预防感染、提供镇痛和治疗炎症的药物产品。
• POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT
  申请人：POLYACTIVA PTY LTD

  公开号：US20180303948A1

  公开（公告）日：2018-10-25

  The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from quinolones, NSAIDs and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click cycloaddition chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the post-surgical care to treat or prevent infections, provide analgesia and treat inflammation.
• BIODEGRADABLE DRUG-POLYMER CONJUGATE
  申请人：POLYACTIVA PTY LTD

  公开号：US20200123322A1

  公开（公告）日：2020-04-23

  A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, β-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.